Business Description

CuraGen Corporation was an early stage biotechnology company that was focused on improving the speed and efficiency of drug development.


Carter Morse & Mathias was engaged during the company’s first year in operation to advise the investors and management and help design a capital formation strategy, assemble a business plan, and to quarterback a capital raising process.


Carter Morse & Mathias assisted in structuring and negotiating the company’s first round of institutional capital in the form of preferred equity capital from a venture capital firm.  Curagen subsequently went public with Morgan Stanley and at its height had a market capitalization of $5 billion.